glp-1 chemical structure glucagon-like peptide 1 Oral Small-Molecule GLP-1 Receptor Agonists:

According to the latest epidemiological data, the number of people with diabetes worldwide has reached 529 million in 2021 and is expected to increase to 1.31 billion by 2050 ( In recent years, Glucagon-like peptide-1 receptor (GLP-1R) and its agonists have attracted much attention in the field of diabetes treatment

This is general information, not medical advice

Choosing the right medication depends on your health history, other medical conditions, and how well you tolerate potential side effects

The gut adjustment period Your gut microbiome is an ecosystem

(4) Although our primary focus was on GLP-1 RAs, we included trials evaluating agents with overlapping mechanisms, such as tirzepatide (dual GIP/GLP-1 RA) and cagrilintide (long-acting amylin analogue), due to their emerging relevance in obesity treatment

[DOI] [PMC free article] [PubMed] [Google Scholar] 74.Feng J, Kang C, Wang C, Ding L, Zhu W, et al